Pediatric VTE Supplement 2: Disclosure of Interests Forms of the Guideline Panel

Caitlin Augustine
Mariana Bonduel
Leonardo Brandao
Tammy Capman
Anthony Chan
Sheila Hanson
Christopher Male
Joerg Meerpohl
Paul Monagle
Fiona Newall
Sara O’Brien
Leslie Raffini
Heleen van Ommen
Sara Vesely
John Wiernikowski
Suzan Williams
Part A. Material Interests in Companies

**Equity**

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No
   ☐ Yes, as described below:

   *Add rows as needed for each equity interest.*

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Patents and Royalties**

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No
   ☐ Yes, as described below:

   *Add rows as needed for each patent or royalty interest.*

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.
Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**My Partner’s or Spouse’s Interests**

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

VTE in Pediatric Populations

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs
1. Do you have strongly held beliefs related to the topic of these guidelines?

☒ No
☐ Yes

If yes, please explain:

Previously Published Opinions
2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

☒ Yes
☐ No

If yes, what were those views and where were they made?

I have authored articles about the need for increased awareness among the general public and healthcare professionals about VTE in children and young adults.
Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☐ No
☐ Yes, as described below:

| Column 1 | Name the entity funding the research. |
| Column 2 | Describe the research project. |
| Column 3 | Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe. |
| Column 4 | Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”) |

Add rows as needed for each research project.

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know
☐ No
☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know
☐ No
Career Advancement
6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

   I believe I would be fully supported.

Advocacy and Policy Positions
7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☒ No
   ☐ Yes

   If yes, are you involved in formulating or voting for positions?

   ☒ No
   ☐ Yes

   If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

   ☐ Don’t know or not applicable
   ☐ No
   ☐ Yes

   If yes, please explain:

Professional Specialty
8. What is your primary clinical specialty or subspecialty?

   Program specialist for the Infectious Disease Department at Tufts Medical Center in Boston, MA.
9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

☒ No
☐ Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☐ No
☒ Yes

If yes, please describe:

I am currently contracted part-time with the National Blood Clot Alliance to do data entry/coordination for their development team. I mainly enter donations into their database from events. I am also a member of the Patient Advocacy Board for the North American Thrombosis Forum. I have done advocacy work for other organizations as well since 2009, but nothing that I feel would affect my decision making for this panel
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on VTE in Pediatric Populations</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Date reviewed by ASH staff</th>
<th>Date confirmed by ASH oversight officer or committee</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>8/13/15</td>
<td>8/15/15</td>
<td></td>
</tr>
</tbody>
</table>

[Add rows as new interests are disclosed and reviewed.]

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:

<table>
<thead>
<tr>
<th>Notes:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>
Part A. Material Interests in Companies

Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No
☐ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patents and Royalties
2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No
☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.
Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Pediatric VTE

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

☐ No
☒ Yes

If yes, please explain:

There has been a dramatic increase of VTE in children related to medical progress in the management of critically and chronically ill patients. Although several aspects like imaging diagnosis, congenital and acquired thrombophilia studies, antithrombotic therapy, short-term outcomes (recurrence, bleeding) and follow-up long-term outcomes (post thrombotic syndrome), have been the subject of research in the last 25 years, evidence-based recommendations remain weak.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

☐ No
☒ Yes

If yes, what were those views and where were they made?
Congress presentations (from 2005 to 2015)


PUBLICATIONS


-Bonduel, M; Sciuccati, G; Hepner, M; Pieroni, G; Feliú Torres, A; Mardaraz, C; Frontroth, JP. Factor V Leiden and prothrombina gene G20210A mutation in children with cerebral thromboembolism. Am J Hematol 2003; 73: 81-86


**Research**

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☐ No

☐ Yes, as described below:

| Column 1 | Name the entity funding the research. |
| Column 2 | Describe the research project. |
| Column 3 | Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe. |
| Column 4 | Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”) |

Add rows as needed for each research project.
Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

The probable debate that this kind of publication could generate is part of the scientific process of the analysis of such an important and, in many aspects, controversial issue.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No
☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable

☐ No

☐ Yes

If yes, please explain:

Professional Specialty
8. What is your primary clinical specialty or subspecialty?

   Pediatric hematologist

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

   Yes, I do. I prescribe such diagnostic tests or treatments because they are currently recommended in the clinical practice for children with VTE.

Expected Interests
10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

    ☒ No

    ☐ Yes

    If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on Pediatric VTE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Reviewer Name and Date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>04/30/2015; 5/5/2015</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>7/2/2018 Alexander</td>
<td>On 6/29/2018, Dr. Bonduel confirmed all information in this form.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
</table>

Notes:
ASH Guideline Panel
Declarations of Interest Form

Part A. Material Interests in Companies

Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

X  No
☐  Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patents and Royalties
2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

X  No
☐  Yes, as described below:

Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

X  No

☐ Yes, as described below:

| Column 1 | Name the company. |
| Column 2 | Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony. |
| Column 3 | Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”) |

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
</table>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

X Yes, as described below:

| Column 1 | Name the company funding or supporting the research. |
| Column 2 | Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution. |
| Column 3 | Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe. |
Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boehringer Ingelheim</td>
<td>1-Dose-finding study; 2- Comparison between standard of care anticoagulation vs. dabigatran in children</td>
<td>Local PI, recruiting for study 1 since 2013; recruiting for study 2 since Feb. 2015</td>
<td>Study 1 likely to end by end of 2015; unsure about study 2</td>
<td>No COI: Boehringer Ingelheim markets dabigatran. Dr. Brandao does not have a leadership role (local PI only), and he said in February 2015 that all of his research funding goes to his institution.</td>
</tr>
<tr>
<td>Bayer</td>
<td>1-Dose-finding study; 2- Comparison between standard of care anticoagulation vs. rivaroxaban in children</td>
<td>Local PI. Recruiting for study 1 since 2014; likely to start recruiting for study 2 during late summer/fall 2015</td>
<td>Study 1 likely to end by end of 2015; unsure about study 2</td>
<td>No COI: Bayer markets rivaroxaban. Dr. Brandao does not have a leadership role (local PI only), and he said in February 2015 that all of his research funding goes to his institution.</td>
</tr>
</tbody>
</table>

My Partner’s or Spouse’s Interests
5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

[X] No

☐ Yes, as described below:

Add rows as needed for each interest.
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

**Pediatric VTE**

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

**Personal Beliefs**

1. Do you have strongly held beliefs related to the topic of these guidelines?

   - [x] No
   - [ ] Yes

   If yes, please explain:

**Previously Published Opinions**

2. Have you ever authored, co-authored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   - [x] No
   - [ ] Yes

   If yes, what were those views and where were they made?

**Research**

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

   - [ ] No
Yes, as described below:

**Column 1** Name the entity funding the research.

**Column 2** Describe the research project.

**Column 3** Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

**Column 4** Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians Service Incorporated Foundation</td>
<td>Fluid accumulation in pediatric post-thrombotic syndrome</td>
<td>PI</td>
<td>August, 2015</td>
</tr>
<tr>
<td>Canadian Pediatric Thrombosis and Hemostasis Network</td>
<td>Anticoagulation Prophylaxis in Pediatric Populations at High Risk for Venous Thrombosis Development.</td>
<td>Co-PI</td>
<td>Summer 2014</td>
</tr>
<tr>
<td>Canadian Pediatric Thrombosis and Hemostasis Network</td>
<td>Practices Towards Low Molecular Weight Heparin Treatment in Children</td>
<td>Co-PI</td>
<td>Summer 2014</td>
</tr>
<tr>
<td>Paediatric Consultants (Sickkids Hospital – 2012), and Stago Inc.</td>
<td>Feasibility Study on the Role of D-dimer in Pediatric Thrombosis</td>
<td>PI; study likely to start during late summer 2015 (funding from Stago yet to be released)</td>
<td>Fall 2017</td>
</tr>
</tbody>
</table>

**Institutional Relationships**

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know

X No

☐ Yes

If yes, please explain:
5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know

X No

☐ Yes

If yes, please explain:

Career Advancement
6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I will receive full support from my division head, as well as from my department head.

Advocacy and Policy Positions
7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

X No

☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No

☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable

☐ No

☐ Yes

If yes, please explain:
Professional Specialty

8. What is your primary clinical specialty or subspecialty?
   Pediatric hematologist with special interest in pediatric thrombosis.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?
   ☐ No
   ☒ Yes

   If yes, please explain: The care of children with thrombotic events and of pediatric patients whose anticoagulation is complicated by bleeding commonly relies on the objective confirmation of such events, which is provided by different imaging techniques. Therefore, as a clinician, I have ordered and will continue to order such tests. The ASH guidelines will, likely, touch on the issues of radiologic imaging sensitivity and specificity for the confirmation of VTE in children, as well as for their potential use during the acute and the non-acute setting, in addition to the respective accuracies of different imaging modalities.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?
    ☒ No
    ☐ Yes

    If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Pediatric VTE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Reviewer Name and Date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>Yes</td>
<td>4/30/2015; 5/5/2015</td>
<td>Dr. Brandao’s status could change if these guidelines address use of D-Dimer and if Stago provides funding for his study described under Part B, question 3.</td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>7/20/2018 Alexander</td>
<td>New disclosure. See Part D. On 6/29/2018, Dr. Brandao confirmed all information in this form.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:
Part D. New Declarations
The following interests were disclosed after appointment:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Internal Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paediatric Consultants (Sickkids Hospital – 2012), and Stago Inc.</td>
<td>Feasibility Study on the Role of D-dimer in Pediatric Thrombosis PI; study likely to start during late summer 2015 (funding from Stago yet to be released)</td>
<td>6/29/2018</td>
<td>Not a COI. This is an update to Part B, Question 3. Stago provided funding for this study. Dr. Brandao has a leadership role, and the subject of the research is related to the guideline topic. However, all funding goes to his institution and these guidelines on pediatric VTE do not address the use of D-dimer.</td>
</tr>
</tbody>
</table>
Part A. Material Interests in Companies

Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☐ No
☒ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>IME Connect, LLC</td>
<td>Meeting and Event Planning Company – we do business with all types of industries, including pharma.</td>
<td>6/1/14</td>
<td>Not a COI: IME Connect does meeting planning and meal planning for pharmaceutical company meetings. The company is not directly involved in the content of any industry meeting.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

**Column 1** Name the company.

**Column 2** Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

**Column 3** Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes...
drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No
☐ Yes, as described below:

<table>
<thead>
<tr>
<th>Column 1</th>
<th>Name the company funding or supporting the research.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Column 2</td>
<td>Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.</td>
</tr>
<tr>
<td>Column 3</td>
<td>Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.</td>
</tr>
<tr>
<td>Column 4</td>
<td>Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)</td>
</tr>
</tbody>
</table>

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
</table>

**My Partner’s or Spouse’s Interests**

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No
☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

VTE in Pediatric Populations

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?
   ☒ No
   ☐ Yes
   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   ☒ No
   ☐ Yes
   If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
   ☒ No
☐ Yes, as described below:

**Column 1** Name the entity funding the research.

**Column 2** Describe the research project.

**Column 3** Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

**Column 4** Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Institutional Relationships**

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know

☒ No

☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know

☒ No

☐ Yes

If yes, please explain:
Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

My son had a large DVT one year ago that was successfully removed. However, in the process we learned that his IVC is completely blocked with hardened clot. My only interest is to learn more due to our ongoing situation and to help others by providing feedback based on our situation and experience.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No
☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☐ No
☐ Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty? Does not apply.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

☒ No
☐ Yes
Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☒ No

☐ Yes

If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on VTE in Pediatric Populations</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Reviewer Name and Date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>8/13/15; 8/15/15</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td></td>
<td>7/20/18 Alexander</td>
<td>On 7/18/2018, Ms. Capman confirmed all information in this form.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:

---

On 7/18/2018, Ms. Capman confirmed all information in this form.
Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No
☐ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

Add rows as needed for each patent or royalty interest.
### Company
**Description** | **Date Divested** | **For ASH Internal Use**
--- | --- | ---
Attwill Medical Solutions Inc – Ontario | Antithrombin-heparin covalent complex in early stage of development | Feb 2015 | Divested before appointment

### Personal Income or Other Remuneration
3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

- [ ] No
- [x] Yes, as described below:

**Column 1** Name the company.

**Column 2** Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

**Column 3** Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

### Company
**Description** | **End Date** | **For ASH Internal Use**
--- | --- | ---
Octapharma | Consultant on use of factor VIII concentrate in hemophilia patients | ongoing | COI: Octapharma makes Octaplex, a warfarin reversal agent.
Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boehringer Ingelheim</td>
<td>Clinical Trial on dabigatran</td>
<td>Member of DSBM for clinical trial</td>
<td>Current</td>
<td>COI: BI markets dabigatran. By email on May 14, 2015, Dr. Chan confirmed that he has received direct payments for this activity from BI.</td>
</tr>
<tr>
<td>Aventis</td>
<td>Clinical trial on a drug development that has stopped</td>
<td>Chair of Steering Committee</td>
<td>Current</td>
<td>Not a COI: By email on May 14, 2015, Dr. Chan explained that this activity has ended. “The account was held by the Hospital also closed.”</td>
</tr>
<tr>
<td>BMS</td>
<td>Clinical trial on comparing US to MRI in diagnosis of VTE</td>
<td>Chair of Adjudication Committee</td>
<td>Current</td>
<td>Not a COI: By email on May 14, 2015, Dr. Chan explained that this activity has</td>
</tr>
<tr>
<td>Company</td>
<td>Description of Research</td>
<td>My Role</td>
<td>End Date</td>
<td>For ASH Internal Use</td>
</tr>
<tr>
<td>----------</td>
<td>------------------------------------------------------</td>
<td>----------------------------------</td>
<td>----------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Bayer</td>
<td>Clinical trial of rivaroxaban in children</td>
<td>Steering Committee for clinical trial</td>
<td>Current</td>
<td>COI: Bayer markets rivaroxaban + leadership role + subject of the research is relevant to the guideline topic. By email on May 14, 2015, Dr. Chan explained: “I was involved in the discussion and design of pediatric trial: when the study is done in my institution, account is held by the institution; all travelling expense for steering committee meeting is paid to me directly.”</td>
</tr>
<tr>
<td>Octapharma</td>
<td>Clinical Study on human cell line factor VIII concentrate</td>
<td>Site PI</td>
<td>ongoing</td>
<td>Not a COI: Octapharma makes Octaplex, a warfarin reversal agent. However, on May 14, 2015, Dr. Chan confirmed that all funds go to his institution. As a site PI, he does not have a leadership role in this research.</td>
</tr>
<tr>
<td>Bayer</td>
<td>Clinical trial on FVIII concentrate</td>
<td>Site PI</td>
<td>ongoing</td>
<td>Not a COI: Bayer markets rivaroxaban; however, by email on May 14, 2015, Dr. Chan confirmed that funds go to his institution.</td>
</tr>
<tr>
<td>Company</td>
<td>Description of Research</td>
<td>My Role</td>
<td>End Date</td>
<td>For ASH Internal Use</td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------</td>
<td>---------</td>
<td>----------</td>
<td>----------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>institution. As a site PI, he does not have a leadership role in this research.</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>Clinical trial on FIX concentrate</td>
<td>Site PI</td>
<td>ongoing</td>
<td>Not a COI: CSL Behring has products related to the treatment of VTE. However, Dr. Chan does not have a leadership role in this research, and by email on May 14, 2015, he confirmed that the funding goes to his institution.</td>
</tr>
</tbody>
</table>

**My Partner’s or Spouse’s Interests**

5. **Currently or in the past 24 months has your partner or spouse** had any of the interests described in questions 1-4?

- ☒ No
- ☐ Yes, as described below:

Add rows as needed for each interest.
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

**Pediatric VTE**

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

**Personal Beliefs**

1. Do you have strongly held beliefs related to the topic of these guidelines?
   - ☒ No
   - ☐ Yes
   
   If yes, please explain:

**Previously Published Opinions**

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   - ☐ No
   - ☒ Yes

   If yes, what were those views and where were they made?

**PEER-REVIEWED PUBLICATIONS**


REVIEWS


BOOKS


BOOK CHAPTERS


Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☒ No

☐ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.
Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

No mentor at this time. McMaster will support me on this academic pursue in my area of expertise
Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes

If yes, are you involved in formulating or voting for positions?

☒ No
☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☒ Don’t know or not applicable
☐ No
☐ Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Pediatric Hematology/Oncology

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

☐ No
☒ Yes

If yes, please explain: I prescribe therapy for patient with thrombotic problem

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?
☒ No
☐ Yes

If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on Pediatric VTE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Reviewer Name and Date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
<td>Yes</td>
<td>05/20/2015; 5/30/2015</td>
<td>New disclosures. See Part D.</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
<td>Yes</td>
<td>03/22/2017 Alexander; 3/24/17 Kunkle</td>
<td>The guideline panel agreed that direct oral anticoagulants (DOACs) are out of scope for all recommendations about anticoagulation because none are approved for use in children. Therefore, companies that market DOACs are not considered affected by these recommendations. This decision reverses some previous decisions about conflicts described in annotations in Parts A and D. The summary of conflicts below is updated and correct.</td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>04/03/2017 Alexander</td>
<td>On 7/5/2018, Dr. Chan confirmed all information in this form.</td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>7/18/2018 Alexander</td>
<td>On 7/5/2018, Dr. Chan confirmed all information in this form.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Company</td>
<td>Description</td>
<td>Disclosure Date</td>
<td>ASH Notes</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td>-----------------</td>
<td>-----------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:
### Part D. New Interests

The following interests were disclosed after appointment:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Internal Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canadian Institutes of Health Research (CIHR)</td>
<td>Fusch, Christoph, Berry Leslie, Brash John, Chan Anthony, Selvaganapathy Ravi, Development of a pumpless lung assist device which acts as an artificial placenta for neonates with respiratory failure, Collab/Partnerships Research Collaborative Health Research Project $273,358.00 Ongoing funding</td>
<td>6/9/2015</td>
<td>Not a COI: CIHR is not an affected company and research is not VTE related.</td>
</tr>
<tr>
<td>Natural Sciences and Engineering Research Council of Canada (NSERC)</td>
<td>Fusch, Christoph, Berry Leslie, Brash John, Chan Anthony, Selvaganapathy Ravi, Development of a pumpless lung assist device which acts as an artificial placenta for neonates with respiratory failure, Collab/Partnerships Research Collaborative Health Research Project, $272,356.00 Ongoing funding</td>
<td>6/9/2015</td>
<td>Not a COI: CIHR is not an affected company and research is not VTE related.</td>
</tr>
<tr>
<td>Daiichi Sankyo</td>
<td>Chair of a steering committee for Daiichi Sankyo funded Phase 1 study for use of edoxaban in pediatric patients</td>
<td>3/21/2017</td>
<td>COI. Daiichi Sankyo markets edoxaban, the research is related to pediatric VTE and Dr. Chan has a leadership role.</td>
</tr>
<tr>
<td>Daiichi Sankyo</td>
<td>Chair of steering committee for a Phase 3 study of edoxaban</td>
<td>3/21/2017</td>
<td>COI. Daiichi Sankyo markets edoxaban, the research is related to pediatric VTE and Dr. Chan has a leadership role.</td>
</tr>
<tr>
<td>Company</td>
<td>Description</td>
<td>Disclosure Date</td>
<td>ASH Internal Notes</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td>-----------------</td>
<td>-------------------</td>
</tr>
<tr>
<td></td>
<td>for treatment of pediatric VTE</td>
<td></td>
<td>pediatric VTE and Dr. Chan has a leadership role.</td>
</tr>
</tbody>
</table>
Part A. Material Interests in Companies

**Equity**

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No
   
   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Patents and Royalties**

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No
   
   ☐ Yes, as described below:

   Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

<table>
<thead>
<tr>
<th>Company funding or supporting the research.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bristol Meyers Squibb</td>
<td>Apixaban Phase I PK pediatric clinical trial. No funding to me. Some funding to our clinical research coordinator and group.</td>
<td>Local Site PI</td>
<td>ongoing</td>
<td>NO COI: BMS markets apixaban but funding goes to Dr. Hanson’s institution and she is not the main PI.</td>
</tr>
</tbody>
</table>

My Partner’s or Spouse’s Interests
5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

<table>
<thead>
<tr>
<th>Topic</th>
<th>Guideline Panel Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venous Thromboembolism (VTE)</td>
<td>VTE Guideline Coordination Panel</td>
</tr>
<tr>
<td>Pediatric VTE</td>
<td>Guideline Panel on Pediatric VTE</td>
</tr>
</tbody>
</table>

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?
   - ☒ No
   - ☐ Yes
   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   - ☒ No
   - ☐ Yes
   If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
   - ☐ No
   - ☒ Yes, as described below:
Column 1  Name the entity funding the research.
Column 2  Describe the research project.
Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.
Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>No funding. Pediatric Trauma Society</td>
<td>Delphi consensus survey regarding role of VTE prophylaxis in injured children</td>
<td>Co-PI</td>
<td>2016</td>
</tr>
<tr>
<td>No funding. Local project.</td>
<td>Outcomes of dual anticoagulation after Fontan surgery</td>
<td>Co-PI</td>
<td>2016</td>
</tr>
<tr>
<td>No funding. Local project.</td>
<td>Sensitivity and specificity of VTE screening for hospitalized children</td>
<td>Co-PI</td>
<td>2015</td>
</tr>
</tbody>
</table>

Institutional Relationships
4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?
   ☐ Don’t know
   ☒ No
   ☐ Yes

   If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?
Career Advancement
6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

My institution would be indifferent regarding the reaction of others towards these guidelines. It would not affect my career advancement.

Advocacy and Policy Positions
7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No

☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No

☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable

☐ No

☐ Yes

If yes, please explain:
Professional Specialty

8. What is your primary clinical specialty or subspecialty?

   Pediatric Critical Care

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

   ☒ Yes

   If yes, please explain: I care for patients who are at risk for VTE and need prevention, diagnosis and treatment.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

    ☒ No

    ☐ Yes

    If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>VTE Guideline Coordination Panel Guideline Panel on Pediatric VTE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Review Name and Date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>4/21/2015; 5/5/2015</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>3/17/2017 Alexander; 3/24/17 Kunkle</td>
<td>New disclosure. See Part D.</td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>Alexander 6/28/2018</td>
<td>On 6/25/2018, Dr. Hanson confirmed all information in this form.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:

<table>
<thead>
<tr>
<th>Notes</th>
<th></th>
</tr>
</thead>
</table>
### Part D. New Declarations

The following interests were disclosed after appointment:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Internal Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>Site PI for a study of enoxaparin prophylaxis in the pediatric ICU to be funded by the American Heart Association. There is no drug company involvement.</td>
<td>3/4/2017</td>
<td>AHA is a nonprofit organization with no VTE products that could be affected by these guidelines. Dr. Hanson’s role in this research on enoxaparin, an anticoagulant marketed by Sanofi, represents a potential indirect or nonfinancial conflict. However, this will be managed through disclosure only.</td>
</tr>
</tbody>
</table>
Part A. Material Interests in Companies

**Equity**

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No

☐ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Patents and Royalties**

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Personal Income or Other Remuneration**

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

<table>
<thead>
<tr>
<th><strong>Company</strong></th>
<th><strong>Description</strong></th>
<th><strong>End Date</strong></th>
<th><strong>For ASH Internal Use</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer</td>
<td>Travel support; speaker remuneration</td>
<td>ongoing</td>
<td>COI: Bayer markets rivaroxaban.</td>
</tr>
<tr>
<td>Baxter</td>
<td>Travel support; speaker remuneration</td>
<td>ongoing</td>
<td>Baxter is not affected by guidelines on this topic. The company no longer markets heparin products and does not have any VTE products currently.</td>
</tr>
<tr>
<td>Biotest</td>
<td>Travel support; speaker remuneration</td>
<td>ongoing</td>
<td>Biotest does not have products that could be affected by guidelines on VTE.</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>speaker remuneration</td>
<td>ongoing</td>
<td>COI: Boehringer Ingelheim markets dabigatran.</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>Travel support; speaker remuneration</td>
<td>ongoing</td>
<td>COI: CSL Behring markets a reversal agent for vitamin K antagonists (Beriplex P/N, Confidex).</td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td>Travel support; speaker remuneration</td>
<td>ongoing</td>
<td>COI: Novo Nordisk markets novoseven, used off label to reverse anticoagulation.</td>
</tr>
</tbody>
</table>

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.
Company | Description | End Date | For ASH Internal Use
--- | --- | --- | ---
Pfizer | Travel support; speaker remuneration | ongoing | COI: Pfizer markets apixaban and daltaparin (a heparin).

### Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

- □ No
- ☒ Yes, as described below:

<table>
<thead>
<tr>
<th>Column 1</th>
<th>Name the company funding or supporting the research.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Column 2</td>
<td>Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.</td>
</tr>
<tr>
<td>Column 3</td>
<td>Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.</td>
</tr>
<tr>
<td>Column 4</td>
<td>Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)</td>
</tr>
</tbody>
</table>

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer</td>
<td>Phase 1-3 trials: oral factor X inhibitor (Rivaroxaban)</td>
<td>Local Investigator</td>
<td>ongoing</td>
<td>Local investigator role does not qualify as a COI. He confirmed on 4/27 that all funding goes to his institution.</td>
</tr>
<tr>
<td>Bayer</td>
<td>Phase 3 trial: recombinant PEGylated FVIII concentrate (PROTECT Study)</td>
<td>Local Investigator</td>
<td>ongoing</td>
<td>Local investigator role does not qualify as a COI. He confirmed on 4/27 that all funding goes to his institution.</td>
</tr>
<tr>
<td>Bayer</td>
<td>Phase 3 trial: unmodified recombinant Factor VIII concentrate</td>
<td>Local Investigator</td>
<td>ongoing</td>
<td>Local investigator role does not qualify as a COI. He confirmed on 4/27 that all funding goes to his institution.</td>
</tr>
<tr>
<td>Company</td>
<td>Description of Research</td>
<td>My Role</td>
<td>End Date</td>
<td>For ASH Internal Use</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>Phase 1-3 trials: oral factor II inhibitor (Dabigatran)</td>
<td>Local Investigator</td>
<td>ongoing</td>
<td>Local investigator role does not qualify as a COI. He confirmed on 4/27 that all funding goes to his institution.</td>
</tr>
<tr>
<td>Bristol-Myers-Squibb</td>
<td>Diagnostic study validating outcome assessment in children with venous thromboembolism</td>
<td>Coordinating investigator</td>
<td>01/2014</td>
<td>Ended before appointment</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>Phase 3 trial: single chain FVIII concentrate</td>
<td>Local Investigator</td>
<td>ongoing</td>
<td>Local investigator role does not qualify as a COI. He confirmed on 4/27 that all funding goes to his institution.</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>Phase 3 trial: recombinant FIX-Albumin fusion protein</td>
<td>Local Investigator</td>
<td>ongoing</td>
<td>Local investigator role does not qualify as a COI. He confirmed on 4/27 that all funding goes to his institution.</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>Phase 4 trial: recombinant Factor VIII concentrate (Helixate), Quality of Life study</td>
<td>Local Investigator</td>
<td>ongoing</td>
<td>Local investigator role does not qualify as a COI. He confirmed on 4/27 that all funding goes to his institution.</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>Phase 3 trial: plasma-derived FVIII/Von Willebrand Factor concentrate (Biostate)</td>
<td>Local Investigator</td>
<td>06/2014</td>
<td>Ended before appointment</td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td>Phase 3 trial: recombinant FVII concentrate (GUARDIAN Study)</td>
<td>Local Investigator</td>
<td>ongoing</td>
<td>Local investigator role does not qualify as a COI. He confirmed on 4/27 that all funding goes to his institution.</td>
</tr>
<tr>
<td>Wyeth/Pfizer</td>
<td>Non-interventional study: recombinant Factor VIII concentrate (Refacto)</td>
<td>Local Investigator</td>
<td>ongoing</td>
<td>Local investigator role does not qualify as a COI. He confirmed on 4/27 that all funding goes to his institution.</td>
</tr>
</tbody>
</table>

**My Partner’s or Spouse’s Interests**

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?
☒ No
☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Pediatric VTE

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

☐ No

☐ Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

☐ No

☐ Yes

If yes, what were those views and where were they made?


Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☐ No
☒ Yes, as described below:

| Column 1 | Name the entity funding the research. |
| Column 2 | Describe the research project. |
| Column 3 | Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe. |
| Column 4 | Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”) |

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Children’s Hospital John Hopkins Medicine (St. Petersburg, FL)</td>
<td>Kids-DOTT trial: comparing 6 weeks versus 3 months of anticoagulation for children with provoked VTE</td>
<td>Local Investigator</td>
<td>ongoing</td>
</tr>
<tr>
<td>Medical University of Vienna, Austria</td>
<td>Randomized controlled trial comparing high-dose versus low-dose heparinization protocols for prophylaxis of thrombotic events during cardiac catheterization in children (HEARTCAT study).</td>
<td>Principal Investigator</td>
<td>Clinical trial completed, analyses ongoing</td>
</tr>
</tbody>
</table>
Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?
   - ☐ Don’t know
   - ☐ No
   - ☒ Yes

   If yes, please explain:
   Graduate and postgraduate teaching, lectures at conferences, symposia, delegate in the Paediatric committee at the European Medicines Agency

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?
   - ☐ Don’t know
   - ☐ No
   - ☒ Yes

   If yes, please explain:
   Benefit from academic contribution

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?
   - Supportive

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?
   - ☐ No
   - ☒ Yes

   If yes, are you involved in formulating or voting for positions?
   - ☐ No
   - ☒ Yes
If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☒ No
☐ Yes

If yes, please explain:

Professional Specialty
8. What is your primary clinical specialty or subspecialty?

Paediatrician, paediatric cardiologist, paediatric coagulation specialist

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

☐ No
☒ Yes

If yes, please explain:

Head of Paediatric Haemostasis and Thrombosis Unit, Dept. Paediatrics, Medical University of Vienna, Austria: personal patient responsibility and internal and external consultation service for the topic

Expected Interests
10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☒ No
☐ Yes

If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on Pediatric VTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved to participate?</td>
<td>Status</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
</tr>
<tr>
<td></td>
<td>Recusal may be required?</td>
</tr>
<tr>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Reviewer Name and Date</td>
</tr>
<tr>
<td></td>
<td>4/30/2015; 5/5/2015</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Notes</td>
</tr>
<tr>
<td></td>
<td>New disclosures. See Part D.</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>4/3/2017 Kunkle</td>
</tr>
<tr>
<td></td>
<td>The guideline panel agreed that</td>
</tr>
<tr>
<td></td>
<td>direct oral anticoagulants (DOACs)</td>
</tr>
<tr>
<td></td>
<td>are out of scope for all</td>
</tr>
<tr>
<td></td>
<td>recommendations about anticoagulation because none are approved for use in children. Therefore, companies that market DOACs are not considered affected by these recommendations. This decision reverses some previous decisions about conflicts described in annotations in Parts A and D. The summary of conflicts below is updated and correct.</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>7/2/2018 Alexander</td>
</tr>
<tr>
<td></td>
<td>On 6/30/2018, Dr. Male confirmed all information in this form.</td>
</tr>
</tbody>
</table>
If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSL Behring</td>
<td>Personal income and travel support for speaking</td>
<td>4/21/15</td>
<td>CSL Behring markets Thrombotrol, human antithrombin III.</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Personal income and travel support for speaking</td>
<td>4/21/15</td>
<td>Pfizer markets daltaparin (a heparin).</td>
</tr>
</tbody>
</table>

Notes:
## Part D. New Interests

The following interests were disclosed after appointment:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Internal Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer</td>
<td>Member of steering committee for study on pediatric development of rivaroxaban</td>
<td>3/15/2017</td>
<td>COI. Bayer markets Rivaroxaban. By email, Dr. Male confirmed that he will receive payment for participating on this steering committee.</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>Member of steering committee for study on use of apixaban in pediatric cardiac patients</td>
<td>3/15/2017</td>
<td>COI. BMS markets apixaban. By email, Dr. Male confirmed that he will receive payment for participating on this steering committee.</td>
</tr>
<tr>
<td>Baxalta</td>
<td>Site PI for study on hemophilia</td>
<td>3/15/2017</td>
<td>Not an affected company.</td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td>Site PI for a study on hemophilia</td>
<td>3/15/2017</td>
<td>Not a COI. Novo Nordisk markets NovoSeven, which is used off label for anticoagulation. However, Dr. Male does not have a leadership role and the study is not related to VTE. By email, Dr. Male confirmed that funding goes to his institution.</td>
</tr>
<tr>
<td>Biotest</td>
<td>Site PI for a study on hemophilia</td>
<td>3/15/2017</td>
<td>Not an affected company.</td>
</tr>
<tr>
<td>Portola Pharmaceuticals</td>
<td>Direct payments for consulting</td>
<td>3/15/2017</td>
<td>Potential COI: Portola is developing a reversal agent and an anticoagulant.</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>Phase 3 trial: single chain FVIII concentrate.</td>
<td>3/15/2017</td>
<td>This trial has ended. Update to Part A,</td>
</tr>
<tr>
<td>Company</td>
<td>Description</td>
<td>Disclosure Date</td>
<td>ASH Internal Notes</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>Phase 4 trial: recombinant Factor VIII concentrate (Helixate), Quality of Life study.</td>
<td>3/15/2017</td>
<td>This trial has ended. Update to Part A, Question 4, Industry-Funded Research.</td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td>Phase 3 trial: recombinant FVII concentrate (GUARDIAN Study)</td>
<td>3/15/2017</td>
<td>This trial has ended. Update to Part A, Question 4, Industry-Funded Research.</td>
</tr>
<tr>
<td>Wyeth/Pfizer</td>
<td>Non-interventional study: recombinant Factor VIII concentrate (Refacto)</td>
<td>3/15/2017</td>
<td>This trial has ended. Update to Part A, Question 4, Industry-Funded Research.</td>
</tr>
</tbody>
</table>
## ASH Guideline Panel
### Declarations of Interest Form

### Part A. Material Interests in Companies

#### Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

- ☒ No

☐ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Patents and Royalties
2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

- ☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.
Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Pediatric VTE

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs
1. Do you have strongly held beliefs related to the topic of these guidelines?
   ☒ No
   ☐ Yes
   If yes, please explain:

Previously Published Opinions
2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   ☒ No
   ☐ Yes
   If yes, what were those views and where were they made?

Research
3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
   ☒ No
☐ Yes, as described below:

Column 1  Name the entity funding the research.

Column 2  Describe the research project.

Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Institutional Relationships

4.  Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:

5.  Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:
Career Advancement
6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Have worked as panel member on WHO dietary guidelines. Always had full support from the director of the German Cochrane Centre and the institution.

Advocacy and Policy Positions
7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No
☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☐ No
☐ Yes

If yes, please explain:

Professional Specialty
8. What is your primary clinical specialty or subspecialty?

Pediatrician, Pediatric Hematologist & Oncologist

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

☒ No (stopped seeing patients about 2 years ago; now only working at German Cochrane Centre as researcher/deputy director)

☐ Yes
If yes, please explain:

Expected Interests
10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☑ No

☐ Yes

If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s) | Guideline Panel on Pediatric VTE
---|---

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Reviewer name and date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>04/14/2015; 4/16/2015</td>
<td></td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
</table>

Notes:

---
ASH Guideline Panel
Declarations of Interest Form

Part A. Material Interests in Companies

Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No
☐ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patents and Royalties
2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ Yes, as described below:
☐ No

US patent, patent no. 8138308, “Modified Peptide Substrate”, issued 20th March 2012

- India patent, patent no. 244241, “Enzyme measurement assay using a modified substrate comprising a substrate attached to a macromolecule via a spacer”, issued 25th November 2010
• China patent application, serial no. 200680053447, “Enzyme Measurement Assay Using A Modified Substrate Comprising A Substrate Attached To A Macromolecule Via A Spacer”, filed 21st December 2006

Co inventors for patent are Dr Anthony chan, Les Berry, Vera Ignjatovic. IP is shared between inventors and McMaster University and University of Melbourne. The patents relate to one invention, which currently does not (and has not for the last 24 months) return any royalties and there is no current licensing agreement with any industry source.

4/30/15 ASH Internal Note: The above patent is not currently used for any product that could be affected by guidelines on pediatric VTE. See Dr. Monagle’s response to Part B, question 10.

Personal Income or Other Remuneration
3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

| Column 1 | Name the company. |
| Column 2 | Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony. |
| Column 3 | Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”) |

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.
### Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

- [ ] No
- ✔ Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Column 1** Name the company funding or supporting the research.

**Column 2** Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

**Column 3** Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

**Column 4** Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.
<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer</td>
<td>Steering Committee for international pediatric randomized trials (unpaid)</td>
<td>I am a local Principal Investigator for my site, however, I do not have the role of a national or overall/coordinating Principal Investigator for any one of the rivaroxaban pediatric trials.</td>
<td>Ongoing</td>
<td>Disclosed 10/23/2014. Role clarified 4/9/15. No COI: Bayer markets rivaroxaban. However, Dr. Monagle does not have a leadership role in this research. He is a member of the Steering Committee, but every study has a named PI.</td>
</tr>
</tbody>
</table>

**My Partner’s or Spouse’s Interests**

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

<table>
<thead>
<tr>
<th>Topic</th>
<th>Guideline Panel Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venous thromboembolism (VTE)</td>
<td>VTE Guideline Coordination Panel</td>
</tr>
<tr>
<td>Pediatric VTE</td>
<td>Guideline Panel on Pediatric VTE</td>
</tr>
</tbody>
</table>

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

☐ No
☒ Yes

If yes, please explain: That our clinical practice should be driven by the best available evidence

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

☐ No
☒ Yes

If yes, what were those views and where were they made?

BOOKS:


BOOK CHAPTERS:


**Formal position papers/ clinical guidelines**


5. Definition of post-thrombotic syndrome following lower extremity deep venous thrombosis and standardization of outcome measurement in pediatric clinical investigations. Goldenberg NA, Brandão L, Journeycake J, Kahn S, **Monagle P**, Revel-vilk S, Sharathkumar A, Chan AK; Perinatal And Paediatric Haemostasis Subcommittee Of The Scientific And Standardization Committee Of The International Society On Thrombosis


Editorials / Reviews


20. Pediatric thrombosis: Where are we after 20 years? Chan AKC, Monagle P, Massicotte MP.


32. We worry about our aim, when we don’t even know the target. Monagle P. Thrombosis Research. 2011 May;127(5):493. Epub 2011 Jan 25. (Journal Impact Factor: 2.440)


Numerous talks and presentations as per CV. No industry sponsored talks in last 5 years. Predominantly talks at national/international/institutional meetings.

### Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☒ No

☐ Yes, as described below:

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know

☐ No

☒ Yes

If yes, please explain: If International conferences (Eg 6th conference and workshop on Thrombosis and Haemostasis, King Saud University Medical Centre, Saudi Arabia) pay honoraria for speaking, then this is paid directly to my University. Honoraria for book chapters etc are paid to my University. My institution derives reputational benefit from my academic work.

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know

☐ No

☒ Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

My institutions trust that I have sufficient knowledge of my field to stand by any opinions or recommendations that I put my name to. I am responsible for driving my institutional protocols in this field.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☐ No

☒ Yes

If yes, are you involved in formulating or voting for positions?
☐ No
☒ Yes
If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?
☐ Don’t know or not applicable
☒ No
☐ Yes
If yes, please explain:

Professional Specialty
8. What is your primary clinical specialty or subspecialty?
   Paediatric Haematology
9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?
   ☒ No
   ☐ Yes
   If yes, please explain: I manage children with thrombotic conditions.

Expected Interests
10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?
   ☒ No
   ☐ Yes
   If yes, please describe:
I am currently discussing applications of my patent with a number of diagnostic test manufacturers. I do not envisage that this will have any direct ramifications to the paediatric guidelines within the foreseeable future. If the patent becomes clinically useful (timeframe of that likely to be greater than 5 years) it will likely relate to primary bleeding disorders, or to monitoring of NOACS, which will not be used in children before studies are completed at around 2020.

I am currently discussing a potential research collaboration with an industry source related to anticoagulation during ECMO, which is not the subject of these guidelines.
I am currently giving advice to Bristol Myers squib about potential trials of apixiban in children. If this continues I am have a role on an international steering committee for a trail, but that would be under the same conditions as my declared role on the current rivaroxaban trials, and I will not accept anything different to those conditions.

Other Interests

Royal Children’s Hospital Foundation. Membership on Board of Directors (not paid). End date = 2013.

Children’s Cancer Centre Foundation. Membership on Board of Directors (not paid). End date = 2012.


Paid expert testimony for State Health Department: Waller vs. James, Supreme Court of New South Wales. Case related to claim of wrongful birth in family history of AT deficiency. End date = 2012.
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>VTE Guideline Coordination Panel</th>
<th>Guideline Panel on Pediatric VTE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Reviewer name and date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>4/30/2015; 5/5/2015</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>6/9/2015</td>
<td>New disclosure. See Part D.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
</table>

Notes:
## Part D. New Interests

The following interests were disclosed after appointment:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Internal Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>Patent application has been accepted for US continuation-in-part patent application, serial no. 13/398379, “Modified Peptide Substrate”, filed 16th February 2012</td>
<td>6/9/15</td>
<td>Not a COI: Patent is not VTE related.</td>
</tr>
<tr>
<td>N/A</td>
<td>Dr. Monagle is no longer a board member for the Murdoch Children’s Research Institute, having stepped down in late 2016.</td>
<td>3/5/2017</td>
<td>This is an update to Part B, Other Interests.</td>
</tr>
<tr>
<td>Bristol Myers Squib</td>
<td>Local investigator and member of the steering committee for a study investigating apixaban for primary prophylaxis of VTE in children with heart disease (Trial DV185362)</td>
<td>3/5/2017</td>
<td>Not a COI. BMS markets apixaban. However, Dr. Monagle does not have a leadership role in this study, does not receive any direct payments from BMS, and the subject of the research is not within scope of these guidelines.</td>
</tr>
<tr>
<td>N/A</td>
<td>Principal investigator for a NHMRC-funded study of anticoagulation in children receiving extracorporeal membrane oxygenation</td>
<td>3/5/2017</td>
<td>Not a COI. The National Health and Medical Research Council is a government organization with no VTE products, and the subject of this research is not within scope of these guidelines.</td>
</tr>
<tr>
<td>Roche</td>
<td>Dr. Monagle is having discussions with Roche about a potential study of their point of care monitor for activated</td>
<td>3/5/2017</td>
<td>Not a COI. Roche markets assays, reagents, and instruments used for anticoagulation testing</td>
</tr>
<tr>
<td>Partial Thromboplastin Time (APTT; a measure of anticoagulation). If the study is funded, Dr. Monagle would not receive any direct payments.</td>
<td>and monitoring. These products are not expected to be specifically addressed by the guidelines.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Stago Diagnostica</strong></td>
<td>Research funding for testing laboratory reagents. Dr. Mongale is not the PI.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Not a COI. Stago Diagnostica markets assays, reagents, and instruments used for anticoagulation testing and monitoring. These guidelines do not address these products. Furthermore, Dr. Monagle does not have a leadership role.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>N/A</strong></td>
<td>Paid expert testimony for a private citizen of Australia: Dr Sinead Cassidy ats Ethan Price. Case related to preventable ICH secondary to haemorrhagic disease of the newborn. End date = 2018.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Not a COI. This testimony was for individuals citizens and did not involve any company that could be affected by these guidelines.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>N/A</strong></td>
<td>Paid expert testimony for a private citizen of Australia: Child and Adolescent Health Service (CAHS) and the East Metropolitan Health Service (EMHS), on instructions from the RiskCover Division of the Insurance Commission of Western Australia. Case related to VTE secondary to osteomyelitis. End date = 2018.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Not a COI. The Child and Adolescent Health Service, East Metropolitan Health Service and the Insurance Commission of Western Australia would not be reasonably affected by ASH guidelines on any topic.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Part A. Material Interests in Companies

### Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   - ☒ No
   - ☐ Yes, as described below:

     Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   - ☒ No
   - ☐ Yes, as described below:

     Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☐ Yes, as described below:

Column 1  Name the company.

Column 2  Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3  Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☑ No

☐ Yes, as described below:

Column 1  Name the company funding or supporting the research.

Column 2  Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.
**Column 3** Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

**Column 4** Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**My Partner’s or Spouse’s Interests**

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☑ No

☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Pediatric VTE

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

☐ No
☒ Yes

If yes, please explain:

I firmly believe in the provision of care that is evidence based. Within paediatric thrombosis, robust evidence is often lacking however this should spur us all onto develop the best consensus guidelines possible to ensure we maximize the likelihood of being able to produce higher quality evidence in the future.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

☐ No
☒ Yes

If yes, what were those views and where were they made?

Recently led the revision of our clinical institution’s Clinical Practice Guidelines for Antithrombotic Therapy that are web-based.
Peer Reviewed Publications


BOOK CHAPTERS


INVITED INTERNATIONAL PRESENTATIONS

2011 XXIII Congress of the International Society of Thrombosis and Haemostasis (Kyoto, Japan) Paediatric Scientific Subcommittee.
- Laboratory monitoring of anticoagulants in children: developing a uniform approach - Heparin monitoring

2011 XXIII Congress of the International Society of Thrombosis and Haemostasis (Kyoto, Japan) Nursing Forum
- Nurse Led Research: Raising the ‘Voice’ of Nursing

2011 XXIII Congress of the International Society of Thrombosis and Haemostasis (Kyoto, Japan) Nursing Forum
- Do we need a Nursing Scientific Subcommittee-style approach to advancing nursing practice in the area of thrombosis and haemostasis?

2009 XXII Congress of the International Society of Thrombosis and Haemostasis (Boston, USA) Paediatric Scientific Subcommittee.
- Quality of Life Tool for Children Receiving Anticoagulant Therapy

2009 XXII Congress of the International Society of Thrombosis and Haemostasis (Boston, USA) Nursing Forum
- Nurse-Driven Research in Haemostasis and Anticoagulation Management: Unfractionated Heparin Therapy in Paediatrics

2009 5th World Congress of Paediatric Cardiology & Cardiac Surgery (Cairns, Australia)
- Anticoagulation Management in the Teenage Population

2008 Pediatric Hemostasis and Thrombosis Update
Hospital for Sick Children (Toronto, Canada)/ The University of Toronto.
- Warfarin Education

2006 Pediatric Hemostasis and Thrombosis Update
Hospital for Sick Children (Toronto, Canada)/ The University of Toronto.
- Warfarin Education

2005 XX Congress of the International Society of Thrombosis and Haemostasis (Sydney, Australia) Paediatric Scientific Subcommittee.
- Thromboprophylaxis in Children Following Cardiothoracic Surgery: Point-of-Care Monitoring.
Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☒ No
☐ Yes, as described below:

<table>
<thead>
<tr>
<th>Column 1</th>
<th>Name the entity funding the research.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Column 2</td>
<td>Describe the research project.</td>
</tr>
<tr>
<td>Column 3</td>
<td>Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.</td>
</tr>
<tr>
<td>Column 4</td>
<td>Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)</td>
</tr>
</tbody>
</table>

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:
5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know
☒ No
☐ Yes
If yes, please explain:

Career Advancement
6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

If the guidelines generated were based on the best available evidence, which would be my expectation, then I would have the support of my primary mentor and institution should strong reaction occur

Advocacy and Policy Positions
7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes
If yes, are you involved in formulating or voting for positions?

☐ No
☐ Yes
If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☐ No
☐ Yes
If yes, please explain:

Professional Specialty
8. What is your primary clinical specialty or subspecialty?
Paediatric Thrombosis and Anticoagulant therapy

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

☐ No
☒ Yes

If yes, please explain:

In the clinical care of patients, I may express a clinical opinion regarding diagnostic tests/treatments that are in the best interests of patients and agreement with best-practice principles.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☒ No
☐ Yes

If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Pediatric VTE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Reviewer Name and Date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>4/15/2015; 4/26/2015</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>7/18/2018 Alexander</td>
<td>On 6/26/2018, Dr. Newall confirmed all information in this form.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:
Part A. Material Interests in Companies

**Equity**

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Patents and Royalties**

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

Column 1 Name the company.
Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.
Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bristol Myers Squibb</td>
<td>Steering Committee Principal Investigator Travel Reimbursement and salary support</td>
<td>Ongoing</td>
<td>COI: BMS/Pfizer market apixaban.</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Steering Committee Personal income</td>
<td>Ongoing</td>
<td>COI: See above. Pfizer also markets dalteparin, a LMWH.</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>Spoke at one education session and attended one education session</td>
<td>February 2014</td>
<td>Ended before appointment</td>
</tr>
</tbody>
</table>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:
Column 1  Name the company funding or supporting the research.

Column 2  Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer</td>
<td>Rivaroxaban Phase II study Funding to institution</td>
<td>Site investigator</td>
<td>Ongoing</td>
<td>Bayer markets rivaroxaban; however, this research does not qualify as a COI because Dr. O’Brien does not have a leadership role and all funding goes to her institution.</td>
</tr>
<tr>
<td>Bayer</td>
<td>Served as consultant for a feasibility project between Bayer and American Thrombosis Hemostasis Network. Funding to institution</td>
<td></td>
<td>December 2014</td>
<td>Ended before appointment</td>
</tr>
<tr>
<td>Ferring</td>
<td>Lysteda study in teens with heavy menses Was investigator initiated study. Ferring provided study drug</td>
<td>PI</td>
<td>March 2015</td>
<td>Ended before appointment</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>Apixaban prophylaxis in newly diagnosed ALL patients Funding to institution</td>
<td>National PI</td>
<td>Ongoing</td>
<td>COI: Dr. O’Brien has a leadership role + BMS is a potentially affected company (apixaban). Research is VTE related.</td>
</tr>
</tbody>
</table>

ASL Guideline Panel Declarations of Interests Form | Page 3
My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No
☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

**Pediatric VTE**

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

**Personal Beliefs**

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No
   ☐ Yes

   If yes, please explain:

**Previously Published Opinions**

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☐ No
   ☒ Yes

   If yes, what were those views and where were they made?

   Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis: discussion.
   **Male C, O'Brien S, Rodriguez V, Mitchell LG.**

   Contraception-related venous thromboembolism in adolescents.
   **O'Brien SH.**
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question.

Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients.
Yee DL, O'Brien SH, Young G.


Research
3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☐ No
☒ Yes, as described below:

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Diabetes Association</td>
<td>Investigating contraception –related VTE in women with diabetes using administrative health claims data</td>
<td>PI</td>
<td>December 2014</td>
</tr>
</tbody>
</table>
| Hemostasis & Thrombosis Research Society    | Lysteda in teens with heavy menstrual bleeding  
Mobile app to measure menstrual bleeding  
Patient registry of women with heavy menses | PI      | June 2015        |
Institutional Relationships
4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:

Career Advancement
6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I have no concerns that I would not continue to receive the strong level of support I currently receive from my mentors and institution.

Advocacy and Policy Positions
7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No
☐ Yes
If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☐ No
☒ Yes

If yes, please explain:

Professional Specialty
8. What is your primary clinical specialty or subspecialty?

Pediatric Hemostasis and Thrombosis

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

☐ No
☒ Yes

If yes, please explain:

My clinical practice involves caring for children with bleeding and clotting disorders

Expected Interests
10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☒ No
☐ Yes

If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on Pediatric VTE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Reviewer Name and Date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
<td>Yes</td>
<td>04/30/2015; 05/05/2015</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
<td>Yes</td>
<td>03/20/2017 Alexander; 03/24/2017 Kunkle</td>
<td>New disclosures. See Part D.</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
<td>Yes</td>
<td>04/03/2017 Kunkle</td>
<td>The guideline panel agreed that direct oral anticoagulants (DOACs) are out of scope for all recommendations about anticoagulation because none are approved for use in children. Therefore, companies that market DOACs are not considered affected by these recommendations. This decision reverses some previous decisions about conflicts described in annotations in Parts A and D. The summary of conflicts below is updated and correct.</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
<td></td>
<td>7/20/2018 Alexander</td>
<td>New disclosures. See Part D. On 7/19/2018, Dr. O’Brien confirmed all information in this form.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:
<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer</td>
<td>Personal income for serving on a steering committee</td>
<td>04/15/2015</td>
<td>Pfizer markets dalteparin, a LMWH.</td>
</tr>
<tr>
<td>Glaxo Smith Kline</td>
<td>Direct payment for participating on a Data Safety and Monitoring Board for fondaparinux study</td>
<td>03/16/2017</td>
<td>GSK markets argatroban and fondaparinux.</td>
</tr>
</tbody>
</table>

Notes:
## Part D. New Declarations

The following interests were disclosed after appointment:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Internal Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glaxo Smith Kline</td>
<td>Direct payment for participating on a Data Safety and Monitoring Board for fondaparinux study</td>
<td>03/16/2017</td>
<td>COI. GSK markets Argatroban and fondaparinux.</td>
</tr>
<tr>
<td>Shire</td>
<td>Direct payment for advisory board on von Willebrand disease</td>
<td>03/16/2017</td>
<td>Not an affected company</td>
</tr>
<tr>
<td>Company</td>
<td>Description</td>
<td>Disclosure Date</td>
<td>ASH Internal Notes</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>-------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td><strong>Perinatal thrombosis: implications for mothers and neonates.</strong> O’Brien SH.</td>
<td></td>
<td>CSL Behring markets a warfarin reversal agent. However, these guidelines on pediatric...</td>
</tr>
<tr>
<td></td>
<td><strong>aPTT in children receiving UFH: time for a change?</strong> Kumar R, O’Brien SH.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>A Review of Hormonal Contraception and Venous Thromboembolism in Adolescents.</strong> Woods GM, Kerlin BA, O’Brien SH, Bonny AE.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSL Behring</td>
<td>Direct payment for serving on an advisory board on von Willebrand disease.</td>
<td>7/19/2018</td>
<td>Not a COI.</td>
</tr>
<tr>
<td>Company</td>
<td><strong>Description</strong></td>
<td><strong>Disclosure Date</strong></td>
<td><strong>ASH Internal Notes</strong></td>
</tr>
<tr>
<td>---------</td>
<td>----------------</td>
<td>--------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>n/a</td>
<td>Direct oral anticoagulants: What will be their role in children? Male, Christoph et al. Thrombosis Research, Volume 0, Issue 0,</td>
<td></td>
<td>VTE do not address the use of warfarin. Update to Part B, Question 2.</td>
</tr>
</tbody>
</table>
Part A. Material Interests in Companies

Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☐ No
☒ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amgen</td>
<td>Stock ownership- $24,000</td>
<td></td>
<td>Amgen does not market any products related to VTE.</td>
</tr>
<tr>
<td>Neurocrine Bioscience</td>
<td>Stock ownership-$5500</td>
<td></td>
<td>Neurocrine Biosciences does not market any products related to VTE.</td>
</tr>
</tbody>
</table>

Patents and Royalties
2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

Add rows as needed for each patent or royalty interest.
<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>UpToDate</td>
<td>I receive royalties for online modules I wrote on Thrombophilia testing in children and on Evaluation of Purpura in Children- ~$1000 per year</td>
<td></td>
<td>Although Wolters Kluwer’s publishing product UpToDate might be affected by the existence of competitor guidelines such as ASH guidelines, it is unlikely to be affected by what ASH guidelines recommend.</td>
</tr>
<tr>
<td>Wolters Kluwer</td>
<td>I am an Associate Editor of Clinical Handbook of Pediatrics and receive royalties- ~$200 per year</td>
<td></td>
<td>As above, this Wolters Kluwer handbook is unlikely to be affected by what ASH guidelines recommend.</td>
</tr>
</tbody>
</table>

**Personal Income or Other Remuneration**

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

- **Column 1**: Name the company.
- **Column 2**: Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.
- **Column 3**: Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.
<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eisai</td>
<td>I am the Chair of the Clinical Adjudication Committee for a Clinical Trial of Dalteparin – this is at a rate of $250/hr and expected to take &lt; 5 hrs in the next year.</td>
<td>5/19/2015</td>
<td>Disclosed 10/22/2014. COI: Eisai markets dalteparin, a LMWH.</td>
</tr>
<tr>
<td>Bayer</td>
<td>I am a member of a Bayer Hemophilia Clinical Advisory Board – this meets twice a year. (up to $8000/yr) – not relevant to pediatric VTE</td>
<td>ongoing</td>
<td>Disclosed 10/22/2014. COI: Bayer markets rivaroxaban.</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>I was a paid consultant for Johnson and Johnson to help design phase I/II clinical trials of Rivoraxaban in children</td>
<td>8/1/2014</td>
<td>Disclosed 10/22/2014. Ended before appointment.</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>I was a paid consultant for GSK in 2013 to attend an FDA meeting and discuss current management of pediatric VTE. GSK manufactures Arixtra ($3680).</td>
<td>5/2013</td>
<td>Disclosed 10/22/2014. Ended before appointment.</td>
</tr>
<tr>
<td>Baxter</td>
<td>Member of Physician leadership council for hemophilia – attended a meeting in Chicago 10/2014 ($2400)</td>
<td>Ongoing annual meetings</td>
<td>Disclosed 10/22/2014. Baxter does not have any VTE-related products.</td>
</tr>
<tr>
<td>Baxter</td>
<td>Travel costs were paid for me to travel to the annual Hemophilia Research Study Update meeting in Berlin 03/2015</td>
<td>03/2015</td>
<td>Disclosed 04/12/2015. Baxter does not have any VTE-related products.</td>
</tr>
<tr>
<td>Glaxo Smith Kline</td>
<td>I recently agreed and signed a contract to participate as a paid member of a Steering Committee for a phase II pediatric study of the anticoagulant Arixtra. This is expected to take 0-4 hrs/month at a rate of $350/hr and last for several years. I am a member of the Steering Committee – the study has not started yet. I think the study will have an overall PI- but that hasn’t been named yet $700 in 2014. I am not directly involved in conducting the research, but serving more as an advisory role.</td>
<td>Ongoing</td>
<td>Disclosed 10/22/2014. COI: GSK markets fondaparinux (Arixtra) and argatroban.</td>
</tr>
</tbody>
</table>
Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1  Name the company funding or supporting the research.

Column 2  Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.
<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

<table>
<thead>
<tr>
<th>Topic</th>
<th>Guideline Panel Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venous thromboembolism (VTE)</td>
<td>VTE Guideline Coordination Panel</td>
</tr>
<tr>
<td>Pediatric VTE</td>
<td>Guideline Panel on Pediatric VTE</td>
</tr>
</tbody>
</table>

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?
   - ☒ No
   - ☐ Yes
   
   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   - ☐ No
   - ☒ Yes (Disclosed 12/11/2014)

   If yes, what were those views and where were they made?

   I speak and write frequently on the topic of management of venous thrombosis in neonates and children. See CV

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
☐ No
☒ Yes, as described below:

**Column 1** Name the entity funding the research.

**Column 2** Describe the research project.

**Column 3** Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

**Column 4** Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NovoNordisk</td>
<td>Clinical trials of Long-acting Factor VIII and Factor IX</td>
<td>I am the local PI of both studies</td>
<td>2016</td>
</tr>
<tr>
<td>Bayer</td>
<td>Phase I, II and III trials of Rivaraxaban in children</td>
<td>I am the local PI of all of these studies</td>
<td>2017</td>
</tr>
<tr>
<td>Center for Disease Control</td>
<td>CDC Registry for Bleeding disorder surveillance</td>
<td>I am the local PI</td>
<td>ongoing</td>
</tr>
<tr>
<td>Baxter</td>
<td>Clinical trial of physical activity and bleeding-SPACE study</td>
<td>I am the local PI</td>
<td>2016</td>
</tr>
<tr>
<td>Biogen</td>
<td>PUP study of long-acting factor VIII and IX- has not yet opened</td>
<td>I am the local PI</td>
<td>ongoing</td>
</tr>
<tr>
<td>Biogen</td>
<td>Clinical study of patients switching to Biogen long-active factor products</td>
<td>I am the local PI</td>
<td>ongoing</td>
</tr>
</tbody>
</table>

5/1/2015 ASH Internal Note: Some of the above funders are pharmaceutical companies. Baxter and Biogen do not have products related to VTE. NovoNordisk has a product used off label for reversal (Novoseven), and Bayer markets rivaroxaban. However, Dr. Raffini does not have a leadership role in these trials.
Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

My division chief and institution would strongly support me. (Disclosed 12/11/2014)

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No
☐ Yes
If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☐ No
☒ Yes

If yes, please explain:

Professional Specialty
8. What is your primary clinical specialty or subspecialty?

Pediatric Hematology (Disclosed 12/11/2014)

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

☐ No
☒ Yes (Disclosed 12/11/2014)

If yes, please explain:

I manage children with thrombosis, the type of this guideline. (Disclosed 12/11/2014)

Expected Interests
10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☒ No
☐ Yes

If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>VTE Guideline Coordination Panel</th>
<th>Guideline Panel on Pediatric VTE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Review Name and Date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
<td>Yes</td>
<td>5/1/2015; 5/5/2015</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
<td>Yes</td>
<td>3/9/2017 Alexander; 3/24/2017 Kunkle</td>
<td>New financial interests disclosed. See Part D.</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
<td>Yes</td>
<td>04/03/2017 Kunkle</td>
<td>The guideline panel agreed that direct oral anticoagulants (DOACs) are out of scope for all recommendations about anticoagulation because none are approved for use in children. Therefore, companies that market DOACs are not considered affected by these recommendations. This decision reverses some previous decisions about conflicts described in annotations in Parts A and D. The summary of conflicts below is updated and correct.</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
<td></td>
<td>7/20/2018 Alexander</td>
<td>New disclosure. See Part D. On 6/22/2018, Dr. Raffini confirmed all information in this form.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:
<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eisai</td>
<td>Personal income from chairing a Clinical Adjudication Committee for a clinical trial of dalteparin</td>
<td>4/10/2015</td>
<td>Eisai markets dalteparin (a heparin).</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>Personal income from serving on a steering committee for a study of fondaparinux</td>
<td>4/10/2015</td>
<td>GSK markets fondaparinux and argatroban.</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>Direct payment for participation in an advisory board</td>
<td>03/06/2017</td>
<td>CSL Behring markets Thrombotrol, human antithrombin III.</td>
</tr>
<tr>
<td>Genentech</td>
<td>Direct payment for participation on an advisory board</td>
<td>03/06/2017</td>
<td>Genentech markets thrombolysis drugs.</td>
</tr>
</tbody>
</table>

Notes:
### Part D. New Declarations

The following interests were disclosed after appointment:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Internal Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSL Behring</td>
<td>Direct payment for participation on an advisory board</td>
<td>03/06/2017</td>
<td>COI. CSL Behring markets Thrombotrol, human antithrombin III.</td>
</tr>
<tr>
<td>Genentech</td>
<td>Direct payment for participation on an advisory board</td>
<td>03/06/2017</td>
<td>COI. Genentech markets thrombolysis drugs.</td>
</tr>
<tr>
<td>Drug Safety Solutions</td>
<td>Direct payment for participation on a data safety and monitoring board</td>
<td>03/06/2017</td>
<td>Not an affected company.</td>
</tr>
<tr>
<td>Green Cross Inc.</td>
<td>Direct payment for consulting</td>
<td>03/06/2017</td>
<td>Not an affected company.</td>
</tr>
<tr>
<td>Hema Biologics, LLC</td>
<td>Direct payment for participation on an advisory board (Jan 2018 – Feb 2018)</td>
<td>6/22/2018</td>
<td>Not an affected company. Hema Biologics does not market any products or devices used in the diagnosis or treatment of VTE.</td>
</tr>
</tbody>
</table>
Part A. Material Interests in Companies

Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No
☐ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patents and Royalties
2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No
☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

**Column 1** Name the company.

**Column 2** Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

**Column 3** Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>GSK</td>
<td>DMC</td>
<td>current</td>
<td>COI: GSK markets fondaparinux and argatroban. (DMC = data monitoring committee.)</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>DMC</td>
<td>current</td>
<td>COI: BI markets dabigatran.</td>
</tr>
<tr>
<td>Daiichi Sankyo</td>
<td>PI Europe phase 3</td>
<td>current</td>
<td>COI: Daiichi Sankyo markets edoxaban.</td>
</tr>
<tr>
<td>Portola</td>
<td>Advisor PIP</td>
<td>current</td>
<td>Possible COI: Portola is developing an anticoagulant reversal agent.</td>
</tr>
</tbody>
</table>

All revenues go to the institution (EKZ AMC) for other thrombotic research.
Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer</td>
<td>Einstein jr</td>
<td>PI</td>
<td>current</td>
<td>Bayer markets rivaroxaban. Although all funding goes to Dr. van Ommen’s institution, she has a leadership role and the subject of this research is relevant to pediatric VTE.</td>
</tr>
<tr>
<td></td>
<td>Funding to institution</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Funding to institution</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No
☐ Yes, as described below:
Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Pediatric VTE

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

☒ No
☐ Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

☐ No
☒ Yes

If yes, what were those views and where were they made?

Thrombophilia: see article Blood: Klaassen IL, van Ommen CH, Middeldorp S. Manifestations and clinical impact of pediatric inherited thrombophilia. Blood. 2015 Feb; 125(7):1073-1077
**Research**

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☐ No
☒ Yes, as described below:

<table>
<thead>
<tr>
<th>Column 1</th>
<th>Name the entity funding the research.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Column 2</td>
<td>Describe the research project.</td>
</tr>
<tr>
<td>Column 3</td>
<td>Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.</td>
</tr>
<tr>
<td>Column 4</td>
<td>Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)</td>
</tr>
</tbody>
</table>

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted grant</td>
<td>Neoclot: treatment of neonates with catheter related thrombosis</td>
<td>National PI</td>
<td>current</td>
</tr>
<tr>
<td>ZonMW grant</td>
<td>Tropicall: prophylactic LMWH in children with ALL treated with asparaginase</td>
<td>National PI</td>
<td>current</td>
</tr>
</tbody>
</table>

**Institutional Relationships**

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:
5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

They will support me.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No
☒ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☒ No
☐ Yes

If yes, please explain:
Professional Specialty
8. What is your primary clinical specialty or subspecialty?
   Pediatric hematologist, specialized in pediatric thrombosis, hemophilia and hemoglobinopathies

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?
   ☒ Yes
   ☐ No

   If yes, please explain:
   I am a pediatric hematologist and treat children with thrombosis, the topic of this guideline.

Expected Interests
10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?
    ☒ No
    ☐ Yes

    If yes, please describe:
# Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on Pediatric VTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved to participate?</td>
<td>Status</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:
<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>GlaxoSmithKline</td>
<td>Personal income for serving on a data monitoring committee</td>
<td>4/29/2015</td>
<td>GSK markets fondaparinux and argatroban.</td>
</tr>
</tbody>
</table>

Notes:
### Part D. New Declarations

The following interests were disclosed after appointment:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Internal Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>GlaxoSmithKline</td>
<td>Personal income for serving on a data monitoring committee. This activity ended in May 2017.</td>
<td>7/25/2018</td>
<td>Not a COI. This is an update to Part A, Question 3.</td>
</tr>
</tbody>
</table>
Part A. Material Interests in Companies

**Equity**

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☐ No

☒ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Incorporated</td>
<td>55 shares, current market value $1913.45</td>
<td></td>
<td>Not a COI: Divested before appointment (May 19, 2015). Confirmed by Dr. Vesely by email on May 26, 2015.</td>
</tr>
</tbody>
</table>

**Patents and Royalties**

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.
### Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

### Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For ASH Internal Use
Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

- **Pediatric VTE**

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

**Personal Beliefs**

1. Do you have strongly held beliefs related to the topic of these guidelines?
   - ☒ No
   - ☐ Yes
   
   If yes, please explain:

**Previously Published Opinions**

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   - ☐ No
   - ☒ Yes

   If yes, what were those views and where were they made?

Methodologist and coauthor on the following guidelines

Research
3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☒ No
☐ Yes, as described below:

<table>
<thead>
<tr>
<th>Column 1</th>
<th>Name the entity funding the research.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Column 2</td>
<td>Describe the research project.</td>
</tr>
<tr>
<td>Column 3</td>
<td>Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.</td>
</tr>
<tr>
<td>Column 4</td>
<td>Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)</td>
</tr>
</tbody>
</table>

Add rows as needed for each research project.

Institutional Relationships
4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:
5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know
☒ No
☐ Yes
If yes, please explain:

Career Advancement
6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

No support

Advocacy and Policy Positions
7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes
If yes, are you involved in formulating or voting for positions?

☐ No
☐ Yes
If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☐ No
☐ Yes
If yes, please explain:
Professional Specialty
8. What is your primary clinical specialty or subspecialty?
   I am a methodologist, specifically a biostatistician. I research hematology, primarily TTP and ITP and I also am Director of the Stephenson Cancer Center Biostatistics Core.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?
   ☒ No
   ☐ Yes
   If yes, please explain:

Expected Interests
10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?
    ☒ No
    ☐ Yes
    If yes, please describe:
## Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on Pediatric VTE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Reviewer Name and Date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>5/1/2015; 5/5/2015</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>9/14/2016 Alexander; 9/23/2016 Kunkle</td>
<td>New interest disclosed. See Part D.</td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>3/20/2017 Alexander; 3/24/2017 Kunkle</td>
<td>New interest disclosed. See Part D.</td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td></td>
<td>9/21/2018 Alexander</td>
<td>On 9/21/2018, Dr. Vesely confirmed all information in this form.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:
Part D. New Declarations
The following interests were disclosed after appointment:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Internal Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ablynx</td>
<td>Statistician for a research project funded by Ablynx to analyze queries from the University of Oklahoma TTP registry</td>
<td>09/13/2016</td>
<td>No COI. Ablynx is not an affected company. By email, Dr. Vesely confirmed that she does not have a leadership role for this project, and all funding goes to her institution.</td>
</tr>
<tr>
<td>Ablynx</td>
<td>Statistician for a research project funded by Ablynx to provide quality of life data from TTP registry to Ablynx for further analysis.</td>
<td>03/14/2017</td>
<td>No COI. Ablynx is not an affected company.</td>
</tr>
</tbody>
</table>
ASH Guideline Panel
Declarations of Interest Form

Part A. Material Interests in Companies

Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No
☐ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patents and Royalties
2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No
☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.
Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☐ No

☒ Yes, as described below: My wife is a Nurse practitioner in adult Haematology and in the past 2 years has done [renumerated] Nursing focused talks for the Pharmaceutical companies listed below. None of these talks deal with treatment or diagnosis of VTE, or anticoagulant medications.

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Celgene</td>
<td>Speakers Bureau</td>
<td>Ongoing</td>
<td>Celgene has no products related to VTE. Confirmed by MP.</td>
</tr>
<tr>
<td>Roche</td>
<td>Speakers Bureau</td>
<td>November 2014</td>
<td>Ended before appointment.</td>
</tr>
<tr>
<td>Janssen</td>
<td>Speakers Bureau</td>
<td>Ongoing</td>
<td>Janssen markets rivaroxaban. By email on June 1, 2015, Dr. Wiernikowski confirmed that his wife “has not done any work with/for Janssen in excess of 1 year, and she will have divest and refrain from doing any</td>
</tr>
<tr>
<td>Company</td>
<td>Description</td>
<td>End Date</td>
<td>For ASH Internal Use</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>----------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Lundbeck</td>
<td>Speakers Bureau</td>
<td>Ongoing</td>
<td>Lundbeck has no products related to VTE. Confirmed by MP.</td>
</tr>
</tbody>
</table>

Work for Janssen for the duration of the guideline development process.”
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

**Pediatric VTE**

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

**Personal Beliefs**

1. Do you have strongly held beliefs related to the topic of these guidelines?
   - ☒ No
   - ☐ Yes
   
   If yes, please explain:

**Previously Published Opinions**

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   - ☐ No
   - ☒ Yes

   If yes, what were those views and where were they made? I co-authored a Review Article on Thrombotic issues in children with cancer in 2006.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☒ No

☐ Yes, as described below:

| Column 1 | Name the entity funding the research. |
| Column 2 | Describe the research project. |
| Column 3 | Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe. |
| Column 4 | Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”) |

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know

☒ No

☐ Yes

If yes, please explain:
5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☑ Don’t know
☐ No
☐ Yes
If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Participation in this panel is supported by my Division Chief and Hospital Management.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes
If yes, are you involved in formulating or voting for positions?

☐ No
☐ Yes
If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☐ No
☐ Yes
If yes, please explain:
Professional Specialty
8. What is your primary clinical specialty or subspecialty?
   Clinical Pharmacist in Pediatric Haematology/Oncology

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?
   ☒ Yes

   If yes, please explain: Part of my professional responsibility includes monitoring of patients undergoing anticoagulation. To that end, I am able to order appropriate tests to accomplish this.

Expected Interests
10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?
    ☒ No

    ☐ Yes

    If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Pane on Pediatric VTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved to participate?</td>
<td>Status</td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:
ASH Guideline Panel
Declarations of Interest Form

Part A. Material Interests in Companies

Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No
☐ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patents and Royalties
2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No
☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.
### Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

- [ ] No
- [x] Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novartis</td>
<td>Cost of travel to attend Global Iron Summit, March 2015</td>
<td>March 15, 2015</td>
<td>Ended before appointment</td>
</tr>
</tbody>
</table>

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.
### Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

- ☐ No
- ☒ Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apopharma</td>
<td>Multicentre randomized trial and the efficacy and safety of Ferriprox compared to Desferal for treatment of transfusional iron overload in patients with sickle cell and other anemias Funding goes to institution</td>
<td>Site PI</td>
<td>Ongoing</td>
<td>No COI: Dr. Williams does not have a leadership role and all funding goes to her institution.</td>
</tr>
<tr>
<td></td>
<td>Cost of travel to attend Investigator’s meeting January 2014</td>
<td></td>
<td>Jan 15, 2014</td>
<td></td>
</tr>
<tr>
<td>Astrazeneca</td>
<td>Multicentre randomized, pharmacokinetic/pharmacodynamic dose ranging study with placebo to drug comparison of ticagrelor in children with sickle cell disease</td>
<td>Site Co- PI, Steering committee Member</td>
<td>Ongoing</td>
<td>No COI: AstraZeneca has no products potentially affected by guidelines on VTE.</td>
</tr>
</tbody>
</table>

Add rows as needed for each research project.
<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bauer</td>
<td>Multicentre, randomized study of safety and efficacy, pharmacokinetics and pharmacodynamics of oral rivaroxaban in children with venous thrombosis</td>
<td>Site Co-PI</td>
<td>ongoing</td>
<td>No COI: Bayer markets rivaroxaban; however, Dr. Williams does not have a leadership role and all funding goes to her institution.</td>
</tr>
<tr>
<td></td>
<td>Funding goes to institution</td>
<td></td>
<td>July 30, 2014</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cost of travel to attend Investigator’s meeting July 2014</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**My Partner’s or Spouse’s Interests**

5. **Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?**

☑ No

☐ Yes, as described below:

*Add rows as needed for each interest.*
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

**Pediatric VTE**

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

**Personal Beliefs**

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No
   ☐ Yes

   If yes, please explain:

**Previously Published Opinions**

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☒ No
   ☐ Yes

   If yes, what were those views and where were they made?

   Evidence-based approach incorporating risk stratification and options for therapy for all topics discussed including:

   - co-author of review article, American society of Pediatric Hematology and Oncology Conference presentation, co-author of chapter in handbook on pediatric hemostasis/thrombosis on diagnosis and management of neonatal portal vein thrombosis
   - co-author of Chapter in handbook on pediatric hemostasis/ thrombosis on deep vein thrombosis
- co-author of Review article and book chapter on pulmonary embolism in children
- International Society on Hemostasis and Thrombosis presentation on pros and cons of thrombophilia testing in children

Research
3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
   ☒ No
   ☐ Yes, as described below:

   Column 1  Name the entity funding the research.
   Column 2  Describe the research project.
   Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.
   Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

   Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Institutional Relationships
4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?
   ☐ Don’t know
   ☒ No
   ☐ Yes
   If yes, please explain:
5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:

Career Advancement
6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Support from mentor and institution would be present and consistent.

Advocacy and Policy Positions
7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No
☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☐ No
☐ Yes

If yes, please explain:
Professional Specialty
8. What is your primary clinical specialty or subspecialty?
   Pediatric Hematology

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?
   ☒ Yes
   □ No
   
   If yes, please explain:
   I am a clinician at a tertiary/quaternary pediatric institution, where 50% of my clinic activities involve the management of children with VTE.

Expected Interests
10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?
    ☒ No
    □ Yes
    
    If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Pediatric VTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved to participate?</td>
<td>Status</td>
</tr>
<tr>
<td></td>
<td>Recusal may be required?</td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
</tr>
</tbody>
</table>

On 7/19/2018, Dr. Williams confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
</table>

Notes: